2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
This guideline cites 6 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2023
- Source
- Marx N, Federici M, et al. Eur Heart J. 2023;44(39):4043–4140.doi 10.1093/eurheartj/ehad192
The 2023 ESC diabetes guideline makes SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular benefit a foundation of care independent of glucose control, and introduces a dedicated SCORE2-Diabetes risk model. The register's landmark cardiovascular-outcome trials are grouped by drug class below.
SGLT2 inhibitors: CV outcomes2
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
GLP-1 receptor agonists2
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2016SUSTAIN-6Endocrinology · GLP-1 RA · CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →
Renal protection in diabetes2
- 2020DAPA-CKD CoreNephrology · CKD · SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
- 2019CREDENCE CoreNephrology · CKD · SGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →
Published since the guideline5
- 2025SURPASS-CVOTCardiology · Cardiometabolic · GIP/GLP-1 RAIn 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior for major adverse cardiovascular events compared with dulaglutide (HR 0.92, 95.3% CI 0.83-1.01).HR 0.9295.3% CI 0.83-1.01Read →
- 2025SOULCardiology · Cardiometabolic · oral GLP-1 RAIn 9,650 patients with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo (HR 0.86, 95% CI 0.77-0.96).HR 0.8695% CI 0.77-0.96Read →
- 2025SURMOUNT-5Cardiology · Cardiometabolic · GIP/GLP-1 RAIn 751 adults with obesity but without type 2 diabetes, tirzepatide reduced body weight at 72 weeks more than semaglutide (-20.2% vs -13.7%).-20.2% vs -13.7%Read →
- 2025SUMMITCardiology · Cardiometabolic · Obesity & HFpEFIn 731 patients with HFpEF and obesity, tirzepatide reduced cardiovascular death or worsening heart failure compared with placebo.HR 0.62Read →
- 2024FLOW CoreNephrology · CKD · GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2023EMPA-KIDNEY
Empagliflozin slowed CKD progression across a broad renal population.
- 2020FIDELIO-DKD
Finerenone reduced renal and CV events in diabetic kidney disease.
- 2017CANVAS
Canagliflozin reduced CV events in type-2 diabetes.
- 2019REWIND
Dulaglutide reduced CV events, largely in primary prevention.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.